These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34621046)

  • 21. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
    King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
    PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
    Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
    Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
    Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H
    Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
    Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
    Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
    Sakai T
    Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS; Crandall H; Dahlman K; Kelley MC
    J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
    Johnson DB; Childress MA; Chalmers ZR; Frampton GM; Ali SM; Rubinstein SM; Fabrizio D; Ross JS; Balasubramanian S; Miller VA; Stephens PJ; Sosman JA; Lovly CM
    Pigment Cell Melanoma Res; 2018 May; 31(3):432-436. PubMed ID: 29171936
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
    PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
    Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
    Chen B; Tardell C; Higgins B; Packman K; Boylan JF; Niu H
    PLoS One; 2012; 7(8):e42598. PubMed ID: 22880048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.